| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of (Rac)-Tenofovir-d6 is not the compound itself but the parent drug Tenofovir, which is a nucleotide reverse transcriptase inhibitor. Tenofovir is used to treat HIV and chronic Hepatitis B (HBV). (Rac)-Tenofovir-d6 is used as an internal standard for the quantification of Tenofovir in pharmacokinetic and bioanalytical studies.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
(Rac)-Tenofovir-d6 itself does not exhibit direct in vitro biological activity because it is a stable isotope-labeled internal standard. However, the parent compound Tenofovir is a nucleotide reverse transcriptase inhibitor. (Rac)-Tenofovir-d6 is used as an internal standard to accurately measure Tenofovir concentrations in biological samples. |
| ln Vivo |
(Rac)-Tenofovir-d6 is not intended for in vivo administration as a therapeutic agent; it is used as an analytical standard. The in vivo activity of the parent compound Tenofovir is well documented as an antiviral agent for HIV and HBV. (Rac)-Tenofovir-d6 is utilized in pharmacokinetic studies to track the distribution, metabolism, and excretion of Tenofovir in biological systems.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (Rac)-Tenofovir-d6 are not typically performed, as it is an analytical standard. Instead, the compound is used in analytical method development and validation. Quality control assays involve HPLC or LC-MS/MS to verify isotopic purity (≥98 atom % D) and chemical purity. The compound is tested for stability under various storage conditions.
|
| Cell Assay |
(Rac)-Tenofovir-d6 itself is not tested in in vitro cellular assays for biological activity, as it is an analytical standard. Its utility is assessed by its performance as an internal standard in analytical workflows, including its ability to provide accurate quantification in LC-MS/MS analyses. The compound is used in quality control applications for Tenofovir analysis.
|
| Animal Protocol |
In vivo animal studies for (Rac)-Tenofovir-d6 are not conducted as therapeutic efficacy studies. Instead, the compound is administered to animals as a tracer in pharmacokinetic studies to quantify the parent drug Tenofovir in plasma, tissues, and excreta. These studies help determine the absorption, distribution, metabolism, and excretion (ADME) profile of Tenofovir.
|
| ADME/Pharmacokinetics |
(Rac)-Tenofovir-d6 has a molecular formula of C9H12D6N5O4P and a molecular weight of 293.25. It has a purity of ≥98% and an isotopic enrichment of ≥98 atom % D. It appears as a solid. The compound is stable under recommended storage conditions. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (Rac)-Tenofovir-d6 is not extensively characterized, as it is an analytical standard rather than a therapeutic agent. The parent compound Tenofovir has well-established safety and toxicity profiles as an antiviral agent. (Rac)-Tenofovir-d6 is intended for research use only and is not approved for clinical use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
(Rac)-Tenofovir-d6 (CAS 1020719-94-1) is the deuterated racemate of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B. (Rac)-Tenofovir-d6 is designed as an internal standard for LC-MS/MS quantitation of tenofovir in biological matrices. It is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
C9H8D6N5O4P
|
|---|---|
| Molecular Weight |
293.25
|
| Exact Mass |
287.078
|
| CAS # |
1020719-94-1
|
| PubChem CID |
45040468
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.53
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
19
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])(C([2H])([2H])N1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
|
| InChi Key |
SGOIRFVFHAKUTI-CUYPRXAISA-N
|
| InChi Code |
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/i1D3,2D2,6D
|
| Chemical Name |
[1-(6-aminopurin-9-yl)-1,1,2,3,3,3-hexadeuteriopropan-2-yl]oxymethylphosphonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4101 mL | 17.0503 mL | 34.1006 mL | |
| 5 mM | 0.6820 mL | 3.4101 mL | 6.8201 mL | |
| 10 mM | 0.3410 mL | 1.7050 mL | 3.4101 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
